Fusion Pharmaceuticals Inc. (FUSN): Price and Financial Metrics
GET POWR RATINGS... FREE!
FUSN Stock Summary
- FUSN's went public 1.76 years ago, making it older than merely 4.37% of listed US stocks we're tracking.
- FUSN's price/sales ratio is 228.99; that's higher than the P/S ratio of 98.72% of US stocks.
- As for revenue growth, note that FUSN's revenue has grown 176.39% over the past 12 months; that beats the revenue growth of 95.32% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Fusion Pharmaceuticals Inc are CRIS, VYGR, SURF, MCRB, and AGLE.
- To check out Fusion Pharmaceuticals Inc's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001805890.
FUSN Valuation Summary
- In comparison to the median Healthcare stock, FUSN's EV/EBIT ratio is 119.8% lower, now standing at -5.8.
- Over the past 14 months, FUSN's price/earnings ratio has gone up 37.9.
- Over the past 14 months, FUSN's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for FUSN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| FUSN | 2021-08-31 | 770.4 | 1.5 | -5.9 | -5.8 |
| FUSN | 2021-08-30 | 777.0 | 1.5 | -6.0 | -5.9 |
| FUSN | 2021-08-27 | 761.2 | 1.5 | -5.9 | -5.7 |
| FUSN | 2021-08-26 | 717.5 | 1.4 | -5.5 | -5.4 |
| FUSN | 2021-08-25 | 693.7 | 1.4 | -5.3 | -5.2 |
| FUSN | 2021-08-24 | 686.2 | 1.4 | -5.3 | -5.1 |
FUSN Price Target
For more insight on analysts targets of FUSN, see our FUSN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $20.20 | Average Broker Recommendation | 1.3 (Strong Buy) |
FUSN Stock Price Chart Interactive Chart >
FUSN Price/Volume Stats
| Current price | $2.53 | 52-week high | $9.50 |
| Prev. close | $2.49 | 52-week low | $2.41 |
| Day low | $2.44 | Volume | 3,300 |
| Day high | $2.56 | Avg. volume | 33,062 |
| 50-day MA | $3.99 | Dividend yield | N/A |
| 200-day MA | $6.17 | Market Cap | 109.66M |
Fusion Pharmaceuticals Inc. (FUSN) Company Bio
Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. The company was founded by John Vaillant and is headquartered in Hamilton, Canada.
Latest FUSN News From Around the Web
Below are the latest news stories about Fusion Pharmaceuticals Inc that investors may wish to consider to help them evaluate FUSN as an investment opportunity.
We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Fusion Pharmaceuticals grants stock options to one employeeFusion Pharmaceuticals (FUSN) announced that the compensation committee of its board granted stock option awards to purchase 12.6K shares of its stock to one employee outside Fusion''s… |
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 12,600 shares of its common stock to one employee outside Fusion's 2020 Stock Option and Incentive Plan. The stock options were granted as an inducement material to the individual becoming an employe |
Fusion Pharmaceuticals to Present at the B. Riley Securities 2022 Virtual Oncology ConferenceFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a fireside chat at the B. Riley Securities 2022 Virtual Oncology Conference on Thursday, January 27, 2022 at 2:00 p.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D. |
Fusion Pharma collaborates with Pepscan to develop peptide-based radiopharmaceuticalsFusion Pharmaceuticals (FUSN) has entered into a strategic research collaboration with Pepscan Therapeutics B.V |
FUSN Price Returns
| 1-mo | -31.06% |
| 3-mo | -66.80% |
| 6-mo | -47.73% |
| 1-year | -68.96% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -39.33% |
| 2021 | -64.51% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...